One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight dropped so much that researchers ...

But now, soaring sales of two blockbuster drugs, the anti-obesity and diabetes treatments Wegovy and Ozempic, have turned this pharmaceutical giant into one of Europe's most valuable companies.

Veru's oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health. In a mid-stage study, patients who received the drug along with Wegovy lost ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target ...

Veru’s oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health. In a mid-stage study, patients who received the drug along with Wegovy lost 71% ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth. Wegovy and Zepbound ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

Wegovy and Zepbound target the GLP-1 protein to help control appetite. Veru was first with results in January from a 168-person trial, showing its enobosarm helped older patients lose 71% less ...

Veru Veru's oral drug ... In a mid-stage study, patients who received the drug along with Wegovy lost 71% less lean, or muscle, mass on average than those who received Wegovy and a placebo ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth. Wegovy and Zepbound target ...